Abstract
Anti TNF-alpha drugs seem to be the new frontier of Rheumatoid Arthritis (RA) therapy. The association infliximab methotrexate has been approved for the treatment of RA not responding to the classic therapy, but the short clinical experience in using antiTNF-alpha molecules brings to segnalation of new risks or adverse events. We describe a case of a patient, treated for many years with classic RA therapy, which developed a refractory anemia after treatment with association infliximab-methotrexate.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Anemia, Refractory, with Excess of Blasts / blood
-
Anemia, Refractory, with Excess of Blasts / chemically induced*
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use
-
Antirheumatic Agents / administration & dosage
-
Antirheumatic Agents / adverse effects*
-
Antirheumatic Agents / therapeutic use
-
Arthritis, Rheumatoid / blood
-
Arthritis, Rheumatoid / complications
-
Arthritis, Rheumatoid / drug therapy*
-
Biopsy, Fine-Needle
-
Bone Marrow / pathology
-
Drug Therapy, Combination
-
Female
-
Humans
-
Infliximab
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects*
-
Methotrexate / therapeutic use
-
Middle Aged
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
Tumor Necrosis Factor-alpha
-
Infliximab
-
Methotrexate